Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for Hu- antigen R
Most Correlated Studies
- L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
- L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
- L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
- L1000 CMAP - Embryonic kidney epithelial HA1E cells treated with ligand perturbagens
Most Relevant Literature
- SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer.
- ELAV-like RNA binding protein 1 regulates osteogenesis in diabetic osteoporosis: Involvement of diva…
- Loss of RNA-Binding Protein HuR Leads to Defective Ependymal Cells and Hydrocephalus.
- Long noncoding RNA 1392 regulates MDA5 by interaction with ELAVL1 to inhibit coxsackievirus B5 infec…
- Srsf1 and Elavl1 act antagonistically on neuronal fate choice in the developing neocortex by control…
Most Relevant Clinical Trials
- Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
- CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
- A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-4…
- CAR-T for r/r Malignant Tumors in Children
- Study of IMPT-314 in R/R Aggressive B-cell
